Product
3F8 Bispecific Antibody
1 clinical trial
3 indications
Indication
NeuroblastomaIndication
OsteosarcomaIndication
Solid Tumor CancersClinical trial
Phase I/II Study of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma, and Other GD2(+) Solid TumorsStatus: Terminated, Estimated PCD: 2021-10-20